Following successful preclinical trials and FDA funding, Cumberland Pharmaceuticals is preparing to launch a new Phase II trial of ifetroban to treat cardiomyopathy in Duchenne Muscular Dystrophy patients.
On Feb. 9, the U.S. Food and Drug Administration approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD).
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: